The Coombs test, also called the antiglobulin test (AGT), is a blood test used to detect antibodies that attack red blood cells. It was developed by Robin Coombs, Arthur Mourant, and Rob Race in 1945 and has since become a foundational test in blood bank medicine, haematology, and obstetric care. The test identifies whether antibodies — produced by the immune system — are attached to the surface of red blood cells or are circulating freely in the serum.
Red blood cells are normally coated only with their own surface proteins. When the immune system mistakenly recognises red blood cells as foreign — or when a patient receives incompatible blood — antibodies attach to the red cell surface and trigger their destruction. This destruction of red blood cells is called haemolysis, and the resulting condition is haemolytic anaemia. The Coombs test detects the antibodies responsible for this process, allowing clinicians to diagnose haemolytic conditions, screen blood for compatibility, and monitor at-risk pregnancies.
There are two main types of Coombs test — direct and indirect — each designed to detect a different aspect of the antibody-red blood cell relationship. The direct Coombs test (DCT) detects antibodies already attached to red blood cells in the patient's circulation. The indirect Coombs test (ICT) detects antibodies circulating freely in the blood serum that have not yet attached to cells. Together, these two variants allow physicians to diagnose a wide range of conditions and to screen for blood incompatibility before transfusions or during pregnancy.
Understanding the Coombs test and what it measures is relevant not only for patients who receive the result but also for those training in medical laboratory science and clinical diagnostics. Medical laboratory technicians and scientists who work in blood bank and transfusion medicine perform and interpret Coombs tests routinely. The test is technically straightforward but requires careful technique, quality controls, and interpretive knowledge — the kind of competency developed through formal lab technician training programmes.
The historical significance of the Coombs test is considerable. Before its development, haemolytic disease of the newborn — caused by Rh incompatibility — was a leading cause of fetal and neonatal death with no reliable diagnostic tool. The test gave clinicians the ability to detect the causative antibodies, monitor their levels during pregnancy, and — with the later development of Rh immunoglobulin — prevent the condition from developing in the first place.
Few diagnostic tests can claim a similar public health impact. Its longevity across nearly eight decades of laboratory medicine is testament to the elegance and reliability of the underlying immunological principle it applies.
A blood sample is drawn by venepuncture, usually from a vein in the arm. The sample is collected into appropriate tubes (typically EDTA anticoagulant tubes for the direct test and plain serum tubes for the indirect test). No special preparation is required from the patient — fasting is not necessary. The sample is labelled precisely, as sample identification is critical in transfusion medicine to prevent errors.
In the laboratory, the blood is centrifuged to separate the red blood cells from the plasma or serum. For the direct Coombs test, the patient's own red blood cells are washed three to six times with saline to remove unbound immunoglobulin from the serum — this washing step is critical to prevent false positives. For the indirect test, the patient's serum is incubated with test red blood cells of known blood group types.
After washing, the Coombs reagent (antihuman globulin, AHG) is added to the cell preparation. This reagent contains antibodies that specifically bind to human immunoglobulins and complement components. If the patient's red blood cells have antibodies attached to them (direct test) or if the patient's serum contains antibodies that have bound to the test cells (indirect test), the AHG causes agglutination — the cells clump together visibly.
Agglutination is the positive result — cells clumping indicates the presence of antibodies. The degree of agglutination is graded from 1+ to 4+ (or recorded as negative). No agglutination is a negative result. The laboratory scientist examines the results visually or using automated systems, adds check cells (sensitised red blood cells) to confirm the test is working correctly, and reports the result with clinical notes for the requesting physician.
The direct and indirect Coombs tests are related but ask different questions, and distinguishing between them is important for interpreting results correctly.
The direct Coombs test (DCT), also called the direct antiglobulin test (DAT), tests the patient's own red blood cells. It answers the question: are there antibodies or complement proteins already bound to the surface of this patient's red blood cells?
A positive DCT indicates that something — the patient's own immune system, an incompatible transfusion, certain drugs, or maternal antibodies in a newborn — has caused antibodies to coat the red blood cells. This is the test ordered when a patient presents with signs of haemolytic anaemia, when a transfusion reaction is suspected, or when haemolytic disease of the newborn (HDN) needs to be confirmed.
The indirect Coombs test (ICT), also called the indirect antiglobulin test (IAT), tests the patient's serum for free-floating antibodies. It answers the question: does this patient's blood contain antibodies that could attack red blood cells — specifically, blood cells of a particular type that the patient might receive?
The ICT is used primarily in two contexts: pre-transfusion compatibility testing (to check that a patient's serum doesn't contain antibodies against donor red blood cells) and prenatal antibody screening (to check whether a pregnant person's blood contains antibodies that could harm the fetus's red blood cells if those cells have a blood group antigen the mother's immune system recognises as foreign).
The most well-known application of the indirect Coombs test in obstetrics is screening for anti-D antibody in Rh-negative pregnant people. If an Rh-negative mother carries an Rh-positive baby, maternal anti-D antibodies can cross the placenta and destroy the baby's red blood cells, causing haemolytic disease of the fetus and newborn (HDFN). The indirect Coombs test detects these antibodies in maternal serum before they reach dangerous levels, allowing prophylactic treatment with Rh immunoglobulin (anti-D) to prevent sensitisation.
AIHA occurs when the immune system produces antibodies that attack the patient's own red blood cells. A positive direct Coombs test is the key diagnostic finding. AIHA can be warm (IgG-mediated, active at body temperature) or cold (IgM-mediated, active at lower temperatures). The Coombs test distinguishes between types and guides treatment with corticosteroids, rituximab, or other immunosuppressive agents.
HDFN occurs when maternal antibodies cross the placenta and destroy fetal red blood cells. The indirect Coombs test in maternal serum screens for the causative antibodies (most commonly anti-D). A positive direct Coombs test on newborn cord blood confirms the condition at delivery. Severity ranges from mild anaemia to fatal hydrops fetalis if untreated.
When a patient receives blood that is incompatible with their own antibodies, a haemolytic transfusion reaction can occur. The direct Coombs test becomes positive after an incompatible transfusion as the patient's antibodies bind to the transfused donor red blood cells. Pre-transfusion compatibility testing (indirect Coombs test) prevents most reactions by screening for incompatibility before transfusion.
Certain drugs — including penicillins, cephalosporins, NSAIDs, and others — can cause a positive Coombs test by adsorbing onto red blood cells or by inducing immune-mediated antibody production. The direct Coombs test is positive, and haemolysis can range from mild to severe. Stopping the causative drug resolves most drug-induced cases.
The direct Coombs test (DAT) tests the patient's own red blood cells for bound antibodies.
The indirect Coombs test (IAT) tests the patient's serum for free-floating antibodies against red blood cells.
Understanding your Coombs test result requires knowing which test was performed and the clinical context.
A positive Coombs test result — whether direct or indirect — indicates the presence of antibodies related to red blood cells. But a positive result isn't a diagnosis in itself. What happens next depends on which test was positive, the strength of the reaction, the patient's clinical presentation, and the results of other laboratory tests.
For a positive direct Coombs test in a patient with anaemia, the next steps typically include a full blood count to quantify the degree of anaemia, a reticulocyte count to assess whether the bone marrow is compensating by producing new red blood cells rapidly, bilirubin and lactate dehydrogenase (LDH) levels to measure the degree of red blood cell breakdown, and a peripheral blood smear to look for red blood cell abnormalities associated with haemolysis. Together, these results tell the physician whether the Coombs-positive antibodies are actually causing clinically significant destruction of red blood cells.
A weakly positive direct Coombs test — particularly a low-grade 1+ reaction — in a patient without anaemia or symptoms of haemolysis is not necessarily clinically significant. Population studies have found that a small percentage of healthy people have a weakly positive direct Coombs test with no apparent disease. In these cases, the finding is noted but may not require treatment or further investigation. The clinical picture, not the test result alone, drives management decisions.
For a positive indirect Coombs test found on pre-transfusion screening, the next step is antibody identification — a blood bank procedure that determines the specific blood group antigen against which the antibody is directed. This identification is essential because different antibodies carry different clinical risks and require different strategies for finding compatible blood.
Some antibodies (like anti-E or anti-c in the Rh system) can cause severe haemolytic transfusion reactions and require antigen-negative blood; others are of limited clinical significance and don't necessitate special blood selection. Medical laboratory technicians who specialise in blood bank perform this antibody identification work, which requires both technical skill and deep knowledge of blood group systems.
The Coombs test has one of its most impactful applications in obstetric medicine, where it protects both mother and fetus from potentially fatal consequences of blood group incompatibility. The indirect Coombs test is a routine part of prenatal care for all pregnant patients, typically performed at the first prenatal visit and again at 28 weeks of pregnancy. The goal is to detect clinically significant antibodies in maternal serum that could cause haemolytic disease of the fetus and newborn (HDFN) by crossing the placenta and destroying fetal red blood cells.
HDFN was historically a major cause of fetal and neonatal death, particularly from Rh incompatibility — specifically, anti-D antibody in Rh-negative mothers carrying Rh-positive babies. The development of Rh immunoglobulin (Rh-Ig, or 'anti-D') prophylaxis in the 1960s, guided by indirect Coombs test monitoring, dramatically reduced the incidence of severe HDFN from Rh incompatibility. Rh-negative pregnant patients receive Rh-Ig prophylaxis at 28 weeks and following delivery (if the baby proves Rh-positive) to prevent sensitisation — the development of anti-D antibodies that would threaten future pregnancies.
Despite this success with Rh disease, HDFN from other blood group antibodies (ABO incompatibility, anti-c, anti-E, anti-Kell, and many others) continues to require vigilant Coombs test monitoring throughout pregnancy. A positive indirect Coombs test during pregnancy triggers a series of responses: antibody identification, titration (measuring how concentrated the antibody is and monitoring it over time), and if the titer reaches a threshold of concern, referral to a fetal medicine specialist for Doppler ultrasound monitoring and potentially intrauterine transfusion if severe fetal anaemia develops.
At delivery, a direct Coombs test on cord blood confirms HDFN in newborns who appear jaundiced or have signs of haemolytic anaemia. Neonates with a positive DCT are monitored for bilirubin levels — if bilirubin rises rapidly, phototherapy (light therapy) or exchange transfusion may be needed to prevent kernicterus, a severe complication of high bilirubin in newborns. Laboratory professionals working in the blood bank perform these critical analyses; understanding the career pathway for medical laboratory technicians who specialise in transfusion medicine reveals the depth of expertise this work requires.
The other common form of HDFN — ABO incompatibility — typically involves a type O mother carrying a type A or B baby. In ABO HDFN, the mother's naturally occurring anti-A and anti-B antibodies (IgG subclass) cross the placenta, but the resulting haemolysis is usually mild and self-limiting. The direct Coombs test may be only weakly positive in ABO HDFN.
This condition rarely requires intervention beyond phototherapy for jaundice and is an important distinction from Rh HDFN, which can be severe. Understanding how the cortisol blood test and other laboratory investigations complement the Coombs test helps build a complete picture of how blood-based diagnostics work together in clinical care.
In modern blood transfusion medicine, the indirect Coombs test — in the form of the antibody screen and crossmatch — is the primary safety check preventing haemolytic transfusion reactions. Every patient who receives a blood transfusion in a hospital undergoes pre-transfusion testing that includes a type and screen (ABO/Rh blood typing + antibody screen) and, if indicated, a full crossmatch against the specific donor unit.
The antibody screen uses the indirect Coombs technique to test the patient's serum against a panel of reagent red blood cells expressing all clinically significant blood group antigens. A negative screen means the patient's serum doesn't contain any common clinically significant antibodies — most transfusions in negative-screen patients can proceed using an electronic or immediate-spin crossmatch without performing the full indirect Coombs crossmatch. This speeds up blood availability in routine situations without compromising safety.
A positive antibody screen requires full antibody identification and antigen-negative blood selection. This process — finding compatible units in the blood bank inventory — can take 30 minutes to several hours depending on the complexity of the antibody and the available inventory. Patients with multiple antibodies, rare antibodies, or alloimmunisation from previous transfusions or pregnancies may require rare blood from a national rare donor registry. In these cases, pre-transfusion testing prevents potentially fatal haemolytic reactions that would otherwise occur.
Major haemolytic transfusion reactions are uncommon precisely because of the rigour of pre-transfusion Coombs testing. When reactions do occur, they often involve clerical errors (wrong blood given to wrong patient) rather than laboratory failures — emphasising that safe transfusion requires not just the technical test but careful sample labelling, patient identification, and process adherence throughout the transfusion chain.
For patients with chronic transfusion needs — those with sickle cell disease, thalassaemia, or bone marrow failure — the management of alloimmunisation (the development of multiple antibodies from repeated exposure to donor red blood cells) is a specialised blood bank challenge. These patients' pre-transfusion Coombs testing becomes increasingly complex with each new antibody, and close collaboration between the blood bank and the clinical team is essential to ensuring both compatibility and timely availability of blood. The Coombs test is the continuous thread running through this long-term management, generating the antibody data that guides every transfusion decision throughout the patient's care.
The Coombs test sits at the intersection of blood bank technology and clinical diagnostics — two areas central to the medical laboratory science profession. Medical laboratory technicians (MLTs) and medical laboratory scientists (MLSs) who work in hospital blood banks perform Coombs testing as part of their daily work, whether for routine pre-transfusion screening, pregnant patient monitoring, or haemolytic anaemia workups. The technical competency required is substantial: mastering the Coombs technique, understanding blood group systems, performing antibody identification, and exercising judgement about when results require clinical escalation.
The medical laboratory profession is a career path that offers a combination of technical challenge, clinical impact, and job stability that is not always visible to people outside the healthcare sector. Blood bank specialists, in particular, play a direct role in patient safety during transfusions and in protecting pregnancies from HDFN — high-stakes work that rarely receives public recognition. If you're considering a career in this field, reviewing medical laboratory technician training options gives a clear picture of the education requirements and career progression available.
The landscape of laboratory testing continues to evolve. Automated antiglobulin testing platforms are increasingly used in high-volume blood banks, improving throughput and reducing manual technique variability. Molecular blood grouping — genotyping red blood cell antigens directly from DNA — is being implemented alongside traditional serological testing to resolve complex cases and to identify compatible blood for patients with rare antibody profiles.
The Coombs test itself, though nearly 80 years old, remains the foundational tool in this evolving landscape — its simplicity and diagnostic power have made it resilient to technological change even as the systems supporting it have become more sophisticated.